Company Overview and News

0
Centrum Capital Limited - Shareholders meeting

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital Limited - Shareholders meeting

2018-05-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

59
Airbus, Lockheed Rush to Tap India's $620 Billion Defense Market - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
501150 LMT DUAVF AM CENTRUM AIR BOE SAABF BA

0
Centrum Capital Limited - Shareholders meeting

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital Limited - Updates

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital on radar as it sells forex arm

2018-04-03 thehindubusinessline
Shares of Centrum Capital will remain in investors’ focus, as the Centrum group has decided to exit its forex business under the brand name Centrum Direct, by selling it to Atlanta-based Ebix Inc for about ₹1,200 crore. As part of the deal, the entire Centrum Direct team and assets will be transferred to Ebix and will become part of EbixCash, an end-to-end financial exchange.
501150 CENTRUM

1
Ebix Takes Leadership Position in India’s Foreign Exchange and Outward Remittance Markets with Agreement to Acquire CentrumDirect Limited

2018-04-03 globenewswire
JOHNS CREEK, Ga., April 03, 2018 (GLOBE NEWSWIRE) -- Ebix, Inc. (NASDAQ:EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, e-governance and healthcare industries, today announced that it has entered into an agreement to acquire India based CentrumDirect Limited (CDL), the undisputed Leader in India’s Foreign Exchange and outward remittance markets for approximately $175 million.
501150 CENTRUM EBIX

1
UPDATE 1-India's Centrum Group to sell money exchange business to US-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday its parent Centrum Group had agreed to sell its money exchange business, Centrum Direct, to U.S.-based Ebix Inc for about 12 billion rupees ($184.6 million).
501150 CENTRUM EBIX

0
Centrum group to sell money exchange business to US-based Ebix

2018-04-03 livemint
Bengaluru: India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to US-based Ebix Inc for about Rs1,200 crore ($184.60 million).
501150 CENTRUM

1
India's Centrum Group to sell money exchange business to U.S.-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to U.S.-based Ebix Inc for about 12 billion rupees ($184.60 million).
501150 CENTRUM EBIX

0
Centrum Group looks to enter insurance, stressed assets business

2018-03-13 livemint
Mumbai: Centrum Group is exploring entry into new lines of business such as stressed assets and insurance, even as the group is looking to boost its existing lending businesses with a fund-raise of around Rs500 crore.
501150 513250 CENTRUM JYOTISTRUC

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...